

가

CD<sub>5</sub><sup>+</sup> B -

\*

\*

## Histopathologic Features and CD5<sup>+</sup> B-lymphocyte Expression in the Experimental Allergic Neuritis

Joong-Yang Cho, Won-Jun Choi, Sung-Hun Kim, Jung-Joon Sung, Ho-Jin Kim,  
Kyung-Seok Park, Ki-Young Choi\*, Hyun-Jung Kim, Kwang-Woo Lee

Department of Neurology and Pathology\*, College of Medicine, Seoul National University

### - Abstract -

**Background :** The pathogenesis of acute inflammatory demyelinating polyradiculoneuropathy (AIDP), Guillain Barre syndrome (GBS) is not clear, but it has been known that the immune mechanisms play an important role. Authors performed this study to establish an animal model of experimental allergic neuritis (EAN) by immunizing the myelin components of peripheral nerves and to understand the electrophysiological and histopathological features as well as the CD<sub>5</sub><sup>+</sup> B-lymphocyte changes in peripheral bloods in the EAN models.

**Methods :** Lewis rats weighing 150-200 gm were injected subcutaneously in soles two times with total myelin, P0, P1, or P2 proteins purified from the bovine cauda equina. The EAN induction was assessed by evaluating clinical manifestations. The electrophysiological and histopathological features were studied as routine methods. The CD<sub>5</sub><sup>+</sup> B-lymphocytes were double stained using monoclonal FITC conjugated anti-rat CD45RA and R-PE conjugated anti-rat CD<sub>5</sub><sup>+</sup> antibodies and calculated using a fluorescence activated cell sorter (FACS).

**Results :** The EAN animal models were established. In two out of five, in one out of two, in none out of three, and in none out of one Lewis rats injected with purified total myelin, P0, P1, P2 proteins respectively, They showed slow spontaneous motor activity and weak resistance against pulling back by tails. The typical electrophysiological and histologic findings in total protein and P0 induced EAN animal models were the decreased conduction velocity, the decreased compound muscle action potential (CMAP) amplitude and the dispersion phenomenon. The perivascular infiltrates of lymphocytes with focal demyelinating process were found in light microscopy. The CD<sub>5</sub><sup>+</sup> B-lymphocyte expression in three EANs were 2.38%, 3.50% 2.50%, which were not significantly increased, compared with those in normal controls.

**Conclusion :** The EAN animal models were successfully established by injecting the total myelin and P0 myelin and they showed electrophysiological and histological features typical of demyelinating process. However they did not show an increased expression of CD<sub>5</sub><sup>+</sup> B-lymphocyte in peripheral bloods which could be indirect evidence of humoral autoimmunity.

**Key Words :** Guillain Barre syndrome, Experimental allergic neuritis, Autoimmune disease



15.8ml, 30% acrylamide 13.3ml, 1.5M Tris (pH8.8) 10ml, 10% ammonium sulfate 0.4ml TEMED 0.016ml, stacking gel 6.8ml, 30% acrylamide 1.7ml, 1.0M Tris(pH6.8) 1.25ml, 10% ammonium sulfate 0.1ml TEMED 0.01ml  
 total myelin sampling buffer  
 loading 5-6 Coomassie  
 brilliant blue destaining buffer  
 immersion, P<sub>0</sub>, P<sub>1</sub>, P<sub>2</sub>

CD5<sup>+</sup>B-  
 trode) 가  
 가  
 (supramaximum)  
 (CMAP)  
 CMAP (negative peak)  
 (latency), (positive peak)  
 (negative peak)  
 CMAP

2.  
 P<sub>0</sub> (1500ug), P<sub>1</sub>(1000ug),  
 P<sub>2</sub>(1000ug), total myelin(2500ug)  
 ( ) Freund's adjuvant 9-11  
 Lewis rat ( 150-200gm)  
 7  
 가 4

1.5cm 가  
 (CNAP)  
 , CNAP  
 CNAP

Freund's adjuvant

(EAN)

4. EAN

(cauda equina) (nerve root)  
 (sciatic nerve)

가

가

EAN

H & E, Luxol-fast blue  
 Massons trichrome

3. EAN

가

Viking

IV EMG (Nicolet, USA)

ketamine 80mg/kg

(prone position)

(needle electrode)

recording electrode)

(reference elec-

5. EAN

EAN

CD5 B-

(puncture)

CD5<sup>+</sup> B-

Histopaque-1077 (Sigma, St Louis, MO, USA)  
 2,000 rpm 30

PBS

50ul 1 × 10<sup>6</sup>

fluorescein isothiocyanate (FITC)  
 phycoerythrin(PE)

**Table 1.** Experimental allergic neuritis and CD5<sup>+</sup> B-lymphocyte expression.

Lewis rats	Antigens immunized	Methods	Clinical weakness	CD5+B-Impocyte expression
Experimental group				
1	Total myelin	2500ug x2 SC	+	2.38%
2	Total myelin	2500ug x2 SC	+	3.50%
3	P0 protein	1500ug x2 SC	+	2.50%
4	Total myelin	2500ug x2 SC	none	1.25%
5	P0 protein	1500ug x2 SC	none	2.32%
Control group				
1	-	-	none	2.66%
2	-	-	none	0.82%

FACScan (Beckon-Dickinson, San Jose, Ca, USA)<sup>15</sup>.  
 가 capping  
 0.04% sodium azide (Sigma, St Louis, MO, USA), 5% heat inactivated FCS Ca<sup>+2</sup>, Mg<sup>+2</sup>  
 PBS  
 CD5+ B-  
 B- CD5  
 FITC conjugated anti-rat CD45RA (Phar-  
 mingen, San Diago, Ca, USA) R-PE conjugat-  
 ed anti-rat CD5 (Pharminogen, San Diago,  
 Ca, USA) air  
 cooled argon FACScan  
 FITC PE  
 , logaris-  
 mic amplification  
 (Figure 3)<sup>16</sup>.

**Table 2.** Motor and Sensory Studies in Normal Lewis Rats

	Mena value (n=11) (mean (SD))	Normal
Motor conduction		
Terminal latency (msec)	0.88 ± 0.10	1.08
Distal CMAP (mv)	7.04 ± 2.4	5.29*
Poroximal CMAP (mv)	5.93 ± 2.29	4.42*
Motor NCV (m/sec)	32.0 ± 3.6	24.8
Sensory conduction		
Sensory CNAP (uv)	7.96 ± 3.0	5.20*
Sensory NCV (m/sec)	33.5 ± 4.5	24.5

CMAP : compound muscle action potential, CNAP : compound nerve action potential, Distal CMAP : stimulated at ankle, Proximal CMAP : stimulated at sciatic notch, \* : lowest amplitude among individual data.

1. (EAN)  
 11 Lewis rat 3 EAN  
 (Table 1). total myelin  
 5 2 , P<sub>0</sub> 2  
 1 , P<sub>1</sub>  
 3 P<sub>2</sub> 가 1 EAN  
 가 total myelin P<sub>0</sub>  
 4 가 .

2. EAN  
 EAN 가  
 EAN 11  
 Lewis rats  
 (terminal latency, TL)  
 0.88±0.10msec, CMAP 7.04±2.4mv  
 , CMAP  
 5.93±2.29mv -  
 (motor NCV) 32 ±  
 가 -  
 (sensory NCV) 33.5±4.5m/sec, CNAP  
 7.96±3.0uv (Table 2).  
 Total myelin EAN (EAN  
 1) 4  
 ,  
 가 2.0msec  
 , CMAP 0.37mv  
 5.29mv ,  
 18.0m/sec (Table 3).  
 CMAP Figure 1

가 CD<sub>5</sub><sup>+</sup>B-

CMAP duration 20.5 msec, 22.3msec (8 10msec) (dis-persion phenomenon) (Fig. 1). 가 -

P0 EAN (EAN 3) 가 0.8msec, 27m/sec, CMAP 6.2mv , 가 15m/sec , CNAP 2.8uv (Table 3). 5.20uv

3. EAN Total myelin (cauda equina) (sciatic nerve) 3 EAN (root) H&E Luxol-fast blue (demyelination) EAN (Fig. 2).


**Table 3. Electrophysiological Features in Experimental Allergic Neuritis Animal Model**

Motor Conduction	EAN animal model			Normal value
	EAN 1	EAN 2	EAN 3	
Terminal latencis (msec)	2.0*	1.0	0.8	1.08
Distal CMAP (mv)	0.37 <sup>†</sup>	1.02*	6.2	5.29
Proximal CMAP(mv)	0.49 <sup>†</sup>	0.74*	5.5	4.42
Motor NCV (m/sec)	18.0*	25.0	27.0	24.8
Sensory Conduction				
CNAP (uv)	NP*	1.79*	2.8*	5.20
Sensory NCV (m/sec)		33.0	15.0*	24.5

\* : mean abnormal findings.


† : mean the increased CMAP duratin and dispersion phenomenon.

4. EAN CD<sub>5</sub><sup>+</sup>B- 11 EAN 3 , EAN 2 , 2 Lewis rat CD<sub>5</sub><sup>+</sup>B- Table 1 FITC conjugated anti-rat CD45RA R- PE conjugated anti-rat CD5 EAN 3 2.38%, 3.50%, 2.50% , 2 2.66%, 0.82% (Fig. 3). EAN CD<sub>5</sub><sup>+</sup>B- 2




**Figure 1.** Electrophysiological features in normal control and EAN 1 animal model. EAN 1 showed markedly decreased amplitude of compound muscle action potential (CMAP), increased duration of CMAP with dispersion phenomenon and decreased motor conduction velocity between ankle-sciatic notch (EAN), compared with those in normal control (CON).

2.66%, 0.82%



**Figure 2.** Histopathological features in nerve root of EAN 1 animal model. H&E and Luxol-fast blue staining of nerve root of cauda equina showed moderate degree of lymphocyte infiltrates in endoneurium (arrow H) and focal demyelination (arrow L), respectively. (H&E x400, Luxol-fast blue x400)

Gullain Barre (GBS) 1 ~ 2 , 3 , 70% (immune mediated) 17. GBS 가 가 가 18, cold agglutinin 가 19, GBS 가 (initiated), GBS (triggered) 20. GBS 가 , total myelin, P<sub>0</sub>, P<sub>1</sub>, P<sub>2</sub>, galactocerebroside P<sub>2</sub> cell-mediated EAN , galactocerebroside humoral immunity EAN 6,8,21,22 total myelin, P<sub>0</sub>, P<sub>1</sub>, P<sub>2</sub> EAN 11



**Figure 3.** CD5 B-lymphocytes expression in peripheral blood in normal control and in EAN 3 animal model. The frequency of CD5 B-lymphocyte in EAN 3 was 2.50% (A), which was not significantly high, compared with 0.82% in normal control (B).

: 가 CD<sub>5</sub><sup>+</sup>B-

, total myelin 5 2 P<sub>0</sub> T- B- ,  
 2 1 EAN rheumatoid arthritis, chronic B-cell leukemia  
 . EAN 가 가 24.  
 가 가 4 가 가  
 가 가 .  
 가 가 CD<sub>5</sub><sup>+</sup> B- 가 가  
 가 가 B-

Total myelin P<sub>0</sub> EAN  
 P<sub>0</sub> total myelin EAN CD<sub>5</sub><sup>+</sup> B- 가 가  
 가 EAN 가 EAN 가

(Table 3). EAN  
 (CMAP) 7.04± . Total  
 2.4mv, CMAP duration 8~10msec, - myelin P<sub>0</sub> EAN  
 bi-phasic , EAN 1 humoral immunity  
 CMAP CMAP duration , CD<sub>5</sub><sup>+</sup> B-  
 2 가 multi-phasic 가 EAN  
 CMAP  
 CMAP duration .  
 가 EAN  
 (degeneration) CD<sub>5</sub><sup>+</sup> B-  
 (demyelination) 가 .  
 P<sub>0</sub>  
 EAN 3

EAN P<sub>0</sub>, P<sub>1</sub>, P<sub>2</sub>, total  
 EAN 1 myelin protein (Lewis  
 (moderate) 가 CD<sub>5</sub><sup>+</sup> B-  
 (Fig. 2). P<sub>0</sub> P<sub>0</sub>, P<sub>1</sub>, P<sub>2</sub>, total myelin 11  
 EAN 3 3 (EAN)  
 가 , total myelin  
 P<sub>0</sub> Waksman Adams EAN 가 EAN  
 . (CMAP)  
 EAN (dispersion phenomenon), CMAP  
 (demyelinating)  
 “ (AIDP)” ,  
 CD<sub>5</sub> EAN  
 (surface marker) CD<sub>5</sub><sup>+</sup> B- 가  
 Leu-1 23. CD<sub>5</sub> Ly-1

(EAN)  
Guillain Barre

가

가

## REFERENCES

1. Ropper AH, Wijdicks EFM, Truax BT. *History of Landry-Guillain-Barre-Strohl syndrome*. In Guillain-Barre Syndrome F.A. Philadelphia, Davis Company, 1991 PP3-17.
2. Pleasure DE and Schotland DL. *Acute neuropathies* : In Lowland LP ed, Merritt 's textbook of Neurology, 8th edition, Philadelphia, Leas Febiger;609-612.
3. Cook SD and Dowling PC. The role of autoantibody and immune complexes in the pathogenesis of Guillain-Barre syndrome. *Ann Neurol* 1981;9(suppl.):70-79.
4. Waksman BH Adams RD. Allergic neuritis. *J Exp Med* 1955; 102:213.
5. Brostoff S, Burnett P, Lampert P. and Eylar EH. Isolation and characterization of a protein from sciatic nerve demyelination responsible for experimental allergic neuritis. *Nature(New Biol.)*1972;235:210-212.
6. Lees MB, Brostoff SW. Proteins of myelin, in : Myelin. *Morell P ed, New York Plenum Press* 1984:197-217.
7. Saida K, Saida T, Brown MJ. and Silberberg DH. In vivo demyelination induced by intraneural injection of anti-galactocerebroside serum: a morphologic study. *Am J Pathol* 1979; 95:99-110.
8. Saida K, Saida T, Pleasure D and Nishitani H. P2 protein-induced experimental allergic neuritis: an ultrastructural study. *J Neurol Sci* 1983;62:77.
9. Saida t, Saida K and Nishitani H. Galactocerebroside-induced experimental allergic neuritis: a possible model of chronic inflammatory demyelinating polyradiculoneuropathy. *Neurol* 1983;33(Suppl.2):82.
10. Latov N, Braun PE, Gross RB. Plasma cell dyscrasia and peripheral neuropathy : identification of the myelin antigens that react with human paraprotein. *Proc Natl Acad Sci* 1981; 78:7139-7142.
11. Koski CL, Humphrey R, Shin ML. antiperipheral myelin antibody in patients with demyelinating neuropathy:quantative and kinetic determination of serum antibody by complement component 1 fixation. *Proc natl Acad Sci USA* 1985;82:905-909.
12. Koski CL. characterization of complement fixing antibodies to peripheral nerve myelin in Guillain-Barre syndrome. *Ann Neurol* 1990;27(suppl)S44-47.
13. Pleasure D. The structural proteins of the peripheral nerve, in : Peripheral neuropathy. Dyck PJ, Thoruas PK, Lambert Ch< Bunge R, eds, Philadelphia, WB Saunders 1984:441-452.
14. Link H, Wahren B and Norrby E. Pleocytosis and immunoglobulin changes in cerebrospinal fluid and herpes virus serology in patients with Guillain-Barre syndrome. *J Clin Microbiol* 1979;9:305-316.
15. Lee KW, Lee SH, Kim HJ, Choi YM, Motomura M. Experimental autoimmune myasthenia gravis and CD5+ B-lymphocyte expression. *J Korean Med Sci.* 1999;14:75-79.
16. Lee KW, Inghirami G, spatz L, Knowles DM, Latov N. The B-cell that express anti-MAG antibodies in neuropathy and non-malignant IgM monoclonal gammopathy belong to the CD5 subpopulation. *J Neuroimmuno* 1991;31:83-89.
17. Behan PO, Lamarche JB, Feldman RG and Sherremata WA. Lymphocyte transformation in the Guillain-Barre syndrome. *Lancet* 1970;i:421.
18. Cook S, Dowling PC and Whitaker JN. The Guillain-Barre syndrome. Relationship of circulating immunocytes to disease activity. *Arch Neurol* 1970;22:470-474.
19. Dowling PC and Cook SD Whitaker JN. Cold agglutinin-positive Guillain-Barre syndrome. *Trans Am Neurol Assoc* 1970; 95:234-235.
20. Fry JM, Weissbarth S, Lehrer GM. Cerebroside antibody inhibits sulfatide synthesis and myelination and demyelination in cord tissue culture. *Science* 1974;183:540-542.
21. Astrom KE, Waksman BH. The passive transfer of experimental allergic encephalomyelitis and neuritis with living lymphoid cells. *J apthol Bacteril* 1962;83:89-105.
22. Linington C., Izumo S and Suzuki M., Uyemura K., Meyermann R. & Wekerle H. A permanent rat T cell line that mediates experimental allergic neuritis in the Lewis rat in vivo. *J Immunl* 1983;133:1946-1950.
23. Ragheb S and Lisak RP. The frequency of CD5 B-lymphocytes in the peripheral blood of patients with myasthenia gravis. *Neurology* 1990;40:1120-4.
24. Casali P, Burastero SE, nakamura M, Inghirami G, Notkins A. Human lymphocytes making rheumatic factor and antibody to ssDNA belong to Leu-1+B-cell subset. *Science* 1987;236:77-81.